MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 90 filers reported holding MARINUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,412,892 | -18.2% | 1,044,948 | +10.3% | 0.00% | 0.0% |
| Q2 2023 | $10,285,093 | +233.3% | 947,062 | +111.8% | 0.00% | – |
| Q1 2023 | $3,085,838 | +185570.2% | 447,223 | +7.1% | 0.00% | – |
| Q4 2022 | $1,662 | -99.9% | 417,729 | +24.6% | 0.00% | – |
| Q3 2022 | $2,228,000 | +39.4% | 335,156 | +1.5% | 0.00% | – |
| Q2 2022 | $1,598,000 | -73.3% | 330,316 | -48.3% | 0.00% | -100.0% |
| Q1 2022 | $5,976,000 | -15.2% | 639,216 | +7.8% | 0.00% | 0.0% |
| Q4 2021 | $7,045,000 | +7.1% | 593,097 | +2.6% | 0.00% | 0.0% |
| Q3 2021 | $6,575,000 | -37.3% | 577,816 | -1.1% | 0.00% | 0.0% |
| Q2 2021 | $10,480,000 | +34.2% | 584,183 | +15.8% | 0.00% | 0.0% |
| Q1 2021 | $7,810,000 | +66.9% | 504,575 | +31.5% | 0.00% | 0.0% |
| Q4 2020 | $4,680,000 | +5.0% | 383,686 | +10.6% | 0.00% | 0.0% |
| Q3 2020 | $4,456,000 | – | 346,798 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |